Welcome everyone to the website of biosim! Through this space the Spanish Association of Biosimilars aims to bring biosimilar medicines closer to the medical community, the health sector in general and, of course, to patients.
Presided over by Joaquín Rodrigo, BioSim sees the light with strategic objectives set without losing sight of the role of biosimilars in the future of the Healthcare System (SNS).
Un biosimilar drug is a biologic that contains a version of the active substance of a reference product to which it has been shown to be equivalent. But, despite the fact that the first biosimilar was approved in Europe in 2004, there is still a significant lack of knowledge about these drugs and their potential.
Thus, various studies indicate that only 25% of doctors know how to define what is a biosimilar and what is not. Hence, there is a need to communicate more about it and clarify the differences, for example, with generic drugs.
Biosim associates include companies such as Accord Biopharmaceuticals, Boehringer Ingelheim, cinfa, Gedeon Richter, Lillly, Kern Pharma, mAbxience, Merck, Mylan, Novartis, R, Sandoz, Sanofi, Stada y Teva.
From biosim We trust that this page will serve as a source of information and dialogue about the past, present and future of biosimilars. Here begins our adventure! Can you come with us?
